

Amendments to the Claims

1-18. (Cancelled)

19. (Previously presented) An aqueous liquid preparation comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, and an alkyl aryl polyether alcohol type polymer or a polyethylene glycol fatty acid ester.

20. (Previously presented) The aqueous liquid preparation according to claim 19, wherein the alkyl aryl polyether alcohol type polymer is tyloxapol;

wherein the concentration of the tyloxapol is selected from a range of about 0.01 w/v % to about 0.5 w/v %; and

wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof is selected from a range of about 0.01 to about 0.5 w/v %.

21. (Previously presented) The aqueous liquid preparation according to claim 20, wherein the pharmacologically acceptable salt of 2-amino-3-(4-bromobenzoyl)phenylacetic acid is a sodium salt.

22. (Previously presented) The aqueous liquid preparation according to claim 21, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is selected from a range of about 0.05 to about 0.2 w/v %.

23. (Previously presented) The aqueous liquid preparation according to claim 22, wherein the concentration of the tyloxapol is selected from a range of about 0.01 w/v % to about 0.3 w/v %.

24. (Previously presented) The aqueous liquid preparation according to claim 23, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is about 0.1 w/v %.

25. (Previously presented) The aqueous liquid preparation according to claim 24, wherein the concentration of the tyloxapol is about 0.02 w/v %.

26. (Previously presented) The aqueous liquid preparation according to claim 25, wherein the formulation further includes one or more additives selected from the group consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

27. (Previously presented) The aqueous liquid preparation according to claim 26, wherein said preservative is benzalkonium chloride; wherein said buffer is boric acid and/or sodium borate; wherein said thickener is polyvinylpyrrolidone; wherein said stabilizer is sodium sulfite; wherein said chelating agent is sodium edetate; and wherein said pH controlling agent is sodium hydroxide.

28. (Previously presented) The aqueous liquid preparation according to claim 27, wherein the pH is from about 7 to about 9.

29. (Previously presented) The aqueous liquid preparation according to claim 28, wherein the pH is from about 7.5 to about 8.5.

30. (Previously presented) The aqueous liquid preparation according to claim 27, wherein said liquid preparation is in the form of an eye drop.

31. (Previously presented) The aqueous liquid preparation according to claim 23, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is about 0.2 w/v %.

32. (Previously presented) The aqueous liquid preparation according to claim 31, wherein the concentration of the tyloxapol is about 0.3 w/v %.

33. (Previously presented) The aqueous liquid preparation according to claim 32, wherein the formulation further includes one or more additives selected from the group consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

34. (Previously presented) The aqueous liquid preparation according to claim 33, wherein said preservative is benzalkonium chloride; wherein said buffer is boric acid and/or sodium borate; wherein said thickener is polyvinylpyrrolidone; wherein said stabilizer is sodium sulfite; wherein said chelating agent is sodium edetate; and wherein said pH controlling agent is sodium hydroxide.

35. (Previously presented) The aqueous liquid preparation according to claim 34, wherein said liquid preparation is in the form of an eye drop.

36. (Previously presented) The aqueous liquid preparation according to claim 31, wherein the concentration of the tyloxapol is about 0.02 w/v %.

37. (Currently amended) The aqueous liquid preparation according to claim 36, wherein the formulation further includes one or more additives selected from the group consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

38. (Previously presented) The aqueous liquid preparation according to claim 37, wherein said preservative is benzalkonium chloride; wherein said buffer is boric acid and/or sodium borate; wherein said thickener is polyvinylpyrrolidone; wherein said chelating agent is sodium edetate; and wherein said pH controlling agent is sodium hydroxide.

39. (Previously presented) A method for stabilizing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof in an aqueous liquid preparation, which comprises incorporating tyloxapol or polyethylene glycol monostearate into an aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof.

40. (Previously presented) A method for inhibiting decrease in preservative effect of a preservative in an aqueous liquid preparation of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, which comprises incorporating tyloxapol or polyethylene glycol monostearate into an aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof and a preservative.